Video

Dr. Harding on Future Directions in the Treatment of Advanced Biliary Tract Cancers

James Harding, MD, discusses future directions in the treatment of patients with advanced biliary tract cancer.

James Harding, MD, gastrointestinal oncologist, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses future directions in the treatment of patients with advanced biliary tract cancer.

Continued efforts are ongoing to evaluate immunotherapy combinations for the treatment of biliary tract cancer, Harding begins. These investigations include novel combinations that were discussed at the 2023 Gastrointestinal Cancers Symposium, including atezolizumab (Tecentriq) plus bevacizumab (Avastin), gemcitabine and capecitabine vs atezolizumab plus gemcitabine and capecitabine in the phase 2 IMbrave 151 trial (NCT04677504). This trial will require further follow-up, Harding notes.

Additionally, investigators are still exploring ways to implement precision medicine in the treatment of biliary tract cancer, Harding continues. Also at the 2023 Gastrointestinal Cancers Symposium, additional data were reported on the use of FGFR inhibitors, including a cohort of patients with FGFR2 fusion–positive cholangiocarcinoma treated with erdafitinib (Balversa) from the phase 2 RAGNAR trial (NCT04083976), Harding notes. Data from study showed an objective response rate of 60.0% (95% CI, 42.1-76.1), which underscores the potential for a precision medicine approach in cholangiocarcinoma, Harding says.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Binod Dhakal, MD
Sheldon M. Feldman, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.